Our critique of these analyses in light of best practices for assessing uncertainty raises concerns about validity and signals that the ICERs and ICURs may be underestimates of the cost-effectiveness of aromatase inhibitors for women with early stage breast cancer. Here, CYP19A1 is linked to breast carcinoma.